ChemoMetec A/S

DB:CHY Stock Report

Market Cap: €1.0b

ChemoMetec Valuation

Is CHY undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CHY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CHY (€60) is trading above our estimate of fair value (€44.63)

Significantly Below Fair Value: CHY is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CHY?

Key metric: As CHY is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for CHY. This is calculated by dividing CHY's market cap by their current earnings.
What is CHY's PE Ratio?
PE Ratio57.2x
EarningsDKK 136.28m
Market CapDKK 7.79b

Price to Earnings Ratio vs Peers

How does CHY's PE Ratio compare to its peers?

The above table shows the PE ratio for CHY vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average65.5x
GXI Gerresheimer
21.7x21.7%€2.5b
1SXP SCHOTT Pharma KGaA
25.7x15.9%€4.0b
SRT3 Sartorius
187.6x36.8%€13.4b
BIO3 Biotest
26.9x82.7%€1.4b
CHY ChemoMetec
57.2x17.2%€7.8b

Price-To-Earnings vs Peers: CHY is good value based on its Price-To-Earnings Ratio (57.2x) compared to the peer average (66.8x).

Price to Earnings Ratio vs Industry

How does CHY's PE Ratio compare vs other companies in the European Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
CHY 57.2xIndustry Avg. 37.1xNo. of Companies4PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: CHY is expensive based on its Price-To-Earnings Ratio (57.2x) compared to the European Life Sciences industry average (37.1x).

Price to Earnings Ratio vs Fair Ratio

What is CHY's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CHY PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio57.2x
Fair PE Ratio16x

Price-To-Earnings vs Fair Ratio: CHY is expensive based on its Price-To-Earnings Ratio (57.2x) compared to the estimated Fair Price-To-Earnings Ratio (16x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CHY forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€60.00
€73.08
+21.8%
0.9%€73.75€72.41n/a2
Nov ’25€53.45
€58.77
+9.9%
16.2%€67.71€45.58n/a3
Oct ’25€53.40
€58.51
+9.6%
16.8%€67.67€44.89n/a3
Sep ’25€50.40
€61.98
+23.0%
2.7%€63.66€60.31n/a2
Aug ’25€51.10
€58.65
+14.8%
8.6%€63.68€53.62n/a2
Jul ’25€40.94
€58.65
+43.3%
8.6%€63.68€53.62n/a2
Jun ’25€45.20
€58.65
+29.8%
8.6%€63.68€53.62n/a2
May ’25€39.28
€61.99
+57.8%
13.5%€70.37€53.62n/a2
Apr ’25€56.40
€60.58
+7.4%
19.2%€70.42€44.26n/a3
Mar ’25€65.50
€60.57
-7.5%
19.2%€70.40€44.25n/a3
Feb ’25€49.26
€60.14
+22.1%
20.4%€70.43€42.93n/a3

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Aspen Pharmacare Holdings

R76.0b

Manufactures and supplies specialty and branded pharmaceutical products worldwide.

LDZA

R8.90

7D

-4.3%

1Y

4.7%

Fortrea Holdings

US$1.7b

A contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide.

K67

US$18.70

7D

-14.2%

1Y

-35.1%

Almirall

€1.8b

A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.

E2Z

€8.44

7D

-3.9%

1Y

-4.0%